VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Announces Marketing Approval of Avanafil in the Russian Federation for the Treatment of Erectile Dysfunction
March 14, 2019 (ACCESSWIRE via COMTEX) -- CAMPBELL, CA / ACCESSWIRE / March 14, 2019 / VIVUS, Inc. VVUS, -1.41% a biopharmaceutical company, today announced that the Ministry of Health of the Russian Federation has approved 50 mg, 100 mg and 200 mg tablets of avanafil for the treatment of erectile
View HTML
Toggle Summary VIVUS Reports Fourth Quarter 2018 Financial Results
Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with
View HTML
Toggle Summary VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019
CAMPBELL, Calif. , Feb. 13, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter and full year of 2018 after the market close on Tuesday, February 26, 2019 .
View HTML
Toggle Summary VIVUS Announces Date of 2019 Annual Meeting
CAMPBELL, Calif. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that the Company will hold its 2019 Annual Meeting of Stockholders (the “2019 Annual Meeting”) on June 5, 2019 .
View HTML
Toggle Summary Data Supporting the Cardiovascular Safety of VIVUS’ Qsymia® Published in The Journal of Clinical Endocrinology & Metabolism
-Study finds no increase in risk for major adverse cardiovascular events for individuals currently using phentermine in combination with topiramate; study adds to robust data supporting the safety and efficacy of Qsymia- CAMPBELL, Calif. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc.
View HTML
Toggle Summary VIVUS to Present at Biotech Showcase on January 9, 2019
CAMPBELL, Calif. , Dec. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that
View HTML
Toggle Summary VIVUS Reports Third Quarter 2018 Financial Results
Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with
View HTML
Toggle Summary VIVUS Adds Two New Members to the Board of Directors
Karen Ferrell and Edward A. Kangas Expand VIVUS’ Board to Nine Members CAMPBELL, Calif. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that Karen Ferrell and Edward A. Kangas have been appointed to VIVUS’ board of
View HTML
Toggle Summary VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Thursday, November 1, 2018
CAMPBELL, Calif. , Oct. 26, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2018 after the market close on Thursday, November 1, 2018. The company will host a conference call beginning
View HTML
Toggle Summary VIVUS to Present at the BIO Investor Forum on October 17, 2018
CAMPBELL, Calif. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that
View HTML